Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients

Song, Hye Yoon; Son, Kyung-Bok; Shin, Ju Young; Bae, Seung Jin

doi:10.1007/s11096-019-00901-8

Cited by 5 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[50,59] On the other hand, two other studies from South Korea reported that 45.8% to 49.4% of patients received undertreatment. [34,67] Of note, the reported rates of undertreatment was much higher in the two retrospective observational studies [34,67] than in the other two prospective ones [50,59], indicating that retrospective studies may overestimate guideline non-adherence. When it comes to overtreatment, prescription of antithrombotic agents in patients who were truly at low-risk for stroke ranged from 53.4% to 58.4%.…”

Section: East Asiamentioning

confidence: 92%

See 1 more Smart Citation

Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence

Gebreyohannes

Salter

Chalmers

et al. 2020

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

show abstract

Section: East Asiamentioning

confidence: 92%

“…[50,59] It is difficult to make comparisons between the different healthcare settings as most of the participants were either from the hospital setting or from a claims database. [34,50,59,67]…”

Section: East Asiamentioning

confidence: 99%

Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence

Gebreyohannes

Salter

Chalmers

et al. 2020

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

show abstract

“…The prescription rate of DOACs for NVAF, after their release in 2011, has increased significantly in recent years, as demonstrated by many other studies, which reported a substantial increase from 14.5% to 70.1%[ 68 , 71 , 80 , 98 , 99 ]. Some of these studies, however, used data from registries of cardiovascular care practices, which may favor enrolment of highly motivated patients under specialist care, and the applicability of these results to the general population may be limited[ 65 ].…”

Section: Discussionmentioning

confidence: 92%

“…Some studies aimed to determine the preference criteria in DOACs use. At patient level, prior stroke, transient ischemic attack, thromboembolism, thyroid disease, dyslipidemia, cancer, HAS-BLED ≥ 5, paroxysmal or non-permanent AF, and the presence of comorbidities were positive predictors of DOACs use over VKAs, whereas young age (≤ 64 years) and renal dysfunction (as they must be used with caution in this latter category of patients) were negative predictors of DOACs use over VKAs[ 57 , 68 , 99 ]. GARFIELD-AF showed that DOACs seemed to be favored for the management of patients with a low stroke risk (CHA 2 DS 2 -VASc 0 or 1)[ 72 ].…”

Section: Discussionmentioning

confidence: 99%

Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation

Abrignani¹,

Lombardo²,

Braschi³

et al. 2022

World J Cardiol

View full text Add to dashboard Cite

BACKGROUND Since 2010, the European Society of Cardiology has extended prescription criteria for oral antithrombotic therapy (OAT) in atrial fibrillation (AF). Direct oral anticoagulants (DOACs) were upgraded from an IIAa recommendation in 2012 to an IA in 2016. In real-world scenarios, however, OAC prescription is still suboptimal, mainly for DOACs. AIM To evaluate OAT temporal prescription patterns in a cohort of patients hospitalized with AF in a Cardiology Department. METHODS A retrospective observational study was conducted on a cohort of hospitalized patients in a secondary setting (Trapani, Italy) from 2010 to 2021 with AF as the main or secondary diagnosis. For 4089 consecutive patients, the variables extracted from the Cardiology department database were: Sex, age, time of hospitalization, antithrombotic therapy (warfarin, acenocoumarol, apixaban, dabigatran, edoxaban, rivaroxaban, aspirin, clopidogrel, other antiplatelet agents, low molecular weight heparin, and fondaparinux), diagnosis at discharge and used resources. Basal features are presented as percentage values for categorized variables and as mean +/- SD for categorized once. RESULTS From January 1st, 2010 to October 6th, 2021, 25132 patients were hospitalized in our department; 4089 (16.27%, mean age 75.59+/-10.82) were discharged with AF diagnosis; of them, 2245 were males (54.81%, mean age 73.56+/-11.45) and 1851 females (45.19%, mean age 78.06+/-9.47). Average length of stay was 5.76+/-4.88 days; 154 patients died and 88 were moved to other Departments/Structures. AF was the main diagnosis in 899 patients (21.94%). The most frequent main diagnosis in patients with AF was acute myocardial infarction (1973 discharges, 48.19%). The most frequent secondary cardiac diagnosis was chronic coronary syndrome (1864 discharges, 45.51%), and the most frequent secondary associated condition was arterial hypertension (1010 discharges, 24.66%). For the analysis of antithrombotic treatments, the final sample included 3067 patients, after excluding in-hospital deaths, transferred out or self-discharged patients, as well as discharges lacking indications for prescribed treatments. OAC treatment increased significantly (35.63% in 2010-2012 vs 61.18% in 2019-2021, +25.55%, P < 0.0001), in spite of any antiplatelet agent use. This rise was due to increasing use of DOACs, with or without antiplatelet agents, from 3.04% in 2013-2015 to 50.06% in 2019-2021 (+47.02%, P < 0.0001) and was greater for factor Xa inhibitors, especially apixaban. In addition, treatment with a vitamin K antagonist, in spite of any antiplatelet agent use, decreased from 35.63% in 2010-2012 to 11.12% in 2019-2021 (-24.48%, P < 0.0001), as well as any antiplatelet therapy, alone or in double combination, (49.18% in 2010-2012 vs 34.18% in 2019-2021, -15.00%,...

show abstract

“…Its principal objective is to avoid the use of federal money to support sex discrimination in educational programs and to protect individual citizens against that action. These programs not only included traditional educational institutions such as schools, colleges and universities but also federally funded training programs including residencies and fellowships [ 28 ].…”

Section: Advocacy For Women In Cardiologymentioning

confidence: 99%

Women in Cardiology: Role of Social Media in Advocacy

Patel

Volgman

2021

CCR

View full text Add to dashboard Cite

: Digital and social media have transformed the field of medicine. They are powerful tools that academic and non-academic physicians and healthcare providers are using to influence others, promote ideas, obtain knowledge, disseminate research and communicate with others. The history of advocacy for women in medicine and the role of social media in influencing the choice of women to choose Cardiology as a career and its role in advocacy for women in cardiology (WIC) have been reviewed. It has changed the way cardiologists learn, educate, and interact with each other. Social media has proven especially useful in advocating for WIC, but whether it can help improve the numbers of female doctors going into Cardiology remains to be seen. In addition to encouraging women to pursue cardiology, social media has drawn attention to key women’s rights issues affecting practicing female cardiologists.

show abstract

Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients

Cited by 5 publications

References 30 publications

Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence

Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence

Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation

Women in Cardiology: Role of Social Media in Advocacy

Contact Info

Product

Resources

About